endometrial carcinoma
Conditions
Interventions
Product Code: Meriva
Pharmaceutical Form: Tablet
INN or Proposed INN: Curcuma Longa Extract
CAS Number: 84775-52-0
Other descriptive name: CURCUMIN E100
Concentration unit: % (W/W) percent weight/weig
Sponsors
UZ Leuven
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Endometrial carcinoma, histologically confirmed No life-threatening metastases Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 5 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5
Exclusion criteria
Exclusion criteria: Other active malignancy Documented autoimmune disease Currently ongoing immunosuppressive therapy Simultaneous treatment according to other clinical trials Documented immune deficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluation of inflammatory markers in blood at regular time points Toxicity;Secondary Objective: Time to development of new metastases Response rate ;Primary end point(s): Effect on inflammatory mediators in blood;Timepoint(s) of evaluation of this end point: day 0, day 1, day 7, day 14, day 21 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Clinical response;Timepoint(s) of evaluation of this end point: baseline and after standard of care treatment | — |
Countries
Belgium
Contacts
Public ContactClinical Trial Information
UZ Leuven
Outcome results
None listed